The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The present disclosure generally relates to the field of infertility, and in particular female infertility. Accordingly, the present disclosure provides for compositions and methods for managing female infertility, caused by Asherman's syndrome. More particularly, the present disclosure provides a therapeutic composition comprising a platelet-derived growth factor concentrate and a thermoresponsive polymer. The present disclosure also relates to the PRP and the concentrate themselves. Consequently, methods to obtain said compositions, along with therapeutic applications for treatment of Asherman's syndrome are also provided.

The present invention relates to a pharmaceutical composition comprising an epidermal growth factor receptor (EGFR) agonist for use in the treatment of a retinal pigment epithelium (RPE) damage associated disease in a patient, wherein the EGFR agonist comprises the EGF family consensus amino acid sequence CX.sub.7CX.sub.4-5CX.sub.10-13CXCX.sub.5GXRC (SEQ ID NO: 1), wherein X is any proteogenic amino acid, wherein the RPE damage associated disease is selected from age-related macular degeneration (AMD), retinitis pigmentosa, cone-rod dystrophies or cone dystrophies, polypoidal choroidal vasculopathy, and Stargardt's disease.

Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro.

Disclosed herein is a method for alleviating arthritis, which includes administering to a subject in need thereof a composition containing epidermal growth factor.

A unit capable of promoting angiogenesis and/or nerve regeneration, including a gel component and proteoglycans, and the like that induces angiogenesis in cells and tissues transplanted into the body, and agents such as scaffolds for neural stem cells to be viable and proliferate after such transplantation.

A unit capable of promoting angiogenesis and/or nerve regeneration, including a gel component and proteoglycans, and the like that induces angiogenesis in cells and tissues transplanted into the body, and agents such as scaffolds for neural stem cells to be viable and proliferate after such transplantation.

The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

Provided herein are methods for the treatment of pancreatitis and/or the prevention of pancreatic cancer. The treatment may comprise the administration of an inducer of acinar-to-ductal metaplasia (ADM), such as an agonist of the mitogen-activated protein kinase (MAPK) signaling pathway, such as a BRAF inhibitor, or an epigenetic modifier, such as a bromodomain extra-terminal motif (BET) inhibitor.

The present invention relates to: a cosmetic composition for improving the condition of the skin, containing, as active ingredients, a cell culture medium, an epidermal growth factor and a bovine serum albumin; a method for improving the condition of the skin by using the same; and a method for preventing or treating skin diseases. According to the present invention, the cosmetic composition can exhibit excellent wrinkle-reducing and wound-healing effects even when only a small amount of EGF is used, and thus can be useful in improving the condition of the skin or in preventing or treating skin diseases.